Neil F. McFarlane

Neil F. McFarlane

President, Chief Executive Officer and DirectoratZevra Therapeutics· In proxies 2023–2025

Pay in FY2024+55% from the year before · Zevra Therapeutics stock +27.3% the same year

Neil F. McFarlane was paid $5.4M in FY2024 (Dec), up 55%. Zevra Therapeutics stock rose 27.3% that year.

Pay$100 in the stock at the end of FY22 → $182
Pay is from the Summary Compensation Table of each Zevra Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Zevra TherapeuticsPublic company · 3 yr
    • President, Chief Executive Officer and Director2023 – Present · 3 yrStock in role +150%
  2. Collegium PharmaceuticalPublic company · 3 yr
    • Director2023 – Present · 3 yrNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?